Long term experience with combination chemotherapy in advanced Hodgkin's disease.
D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001761:Bleomycin / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D007938:Leukemia / Q000139:chemically induced; D008130:Lomustine / Q000627:therapeutic use; D008297:Male; D008466:Mechlorethamine / Q000627:therapeutic use; D008875:Middle Aged; D009153:Mutagens; D009378:Neoplasms, Multiple Primary / Q000139:chemically induced; D010110:Oxymetholone / Q000627:therapeutic use; D011241:Prednisone / Q000627:therapeutic use; D011247:Pregnancy; D011344:Procarbazine / Q000627:therapeutic use; D011929:Razoxane / Q000627:therapeutic use; D013723:Teratogens; D014747:Vinblastine / Q000627:therapeutic use; D014750:Vincristine / Q000627:therapeutic use
D000970:Antineoplastic Agents; D009153:Mutagens; D013723:Teratogens; D001761:Bleomycin; D011344:Procarbazine; D008466:Mechlorethamine; D011929:Razoxane; D014750:Vincristine; D014747:Vinblastine; D008130:Lomustine; D010110:Oxymetholone; D011241:Prednisone